Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Recommendation of “Moderate Buy” by Analysts

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $3.8571.

RVPH has been the subject of several recent analyst reports. D. Boral Capital restated a “buy” rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a research note on Wednesday, November 19th. Maxim Group lowered their price objective on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, August 15th. Citigroup reaffirmed a “buy” rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 15th. HC Wainwright decreased their price target on Reviva Pharmaceuticals from $11.00 to $4.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Wednesday, October 8th.

Institutional Trading of Reviva Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC grew its stake in Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after purchasing an additional 223,178 shares during the last quarter. Lido Advisors LLC acquired a new stake in shares of Reviva Pharmaceuticals during the third quarter worth about $37,000. 683 Capital Management LLC purchased a new stake in Reviva Pharmaceuticals in the second quarter valued at approximately $381,000. Armistice Capital LLC purchased a new stake in Reviva Pharmaceuticals in the second quarter valued at approximately $1,026,000. Finally, XTX Topco Ltd acquired a new position in Reviva Pharmaceuticals in the 2nd quarter worth approximately $31,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Price Performance

RVPH opened at $0.62 on Tuesday. The firm has a market capitalization of $70.96 million, a PE ratio of -1.34 and a beta of -0.02. The business’s 50-day moving average is $0.54 and its two-hundred day moving average is $0.56. Reviva Pharmaceuticals has a 1 year low of $0.25 and a 1 year high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. As a group, sell-side analysts expect that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.